0001078782-16-002133.txt : 20160105
0001078782-16-002133.hdr.sgml : 20160105
20160105173657
ACCESSION NUMBER: 0001078782-16-002133
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160101
FILED AS OF DATE: 20160105
DATE AS OF CHANGE: 20160105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VOLITIONRX LTD
CENTRAL INDEX KEY: 0000093314
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 911949078
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 SCOTTS RD #24-05 SHAW CENTRE
CITY: SINGAPORE
STATE: U0
ZIP: 228208
BUSINESS PHONE: 1 (646) 650-1351
MAIL ADDRESS:
STREET 1: 1 SCOTTS RD #24-05 SHAW CENTRE
CITY: SINGAPORE
STATE: U0
ZIP: 228208
FORMER COMPANY:
FORMER CONFORMED NAME: STANDARD CAPITAL CORP
DATE OF NAME CHANGE: 19990812
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TERRELL JASON BRADLEY MD
CENTRAL INDEX KEY: 0001567531
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36833
FILM NUMBER: 161323992
MAIL ADDRESS:
STREET 1: P.O. BOX 3018
CITY: MARBLE FALLS
STATE: TX
ZIP: 78654
3
1
primary_doc.xml
PRIMARY DOCUMENT
X0206
3
2016-01-01
0
0000093314
VOLITIONRX LTD
VNRX
0001567531
TERRELL JASON BRADLEY MD
1 SCOTTS RD #24-05 SHAW CENTRE
SINGAPORE
U0
228208
SINGAPORE
0
1
0
0
Chief Medical Officer
Common Stock
61364
D
Warrant (Right to Buy)
2.47
Common Stock
25000
D
Warrant (Right to Buy)
2.47
Common Stock
25000
D
Warrant (Right to Buy)
2.47
Common Stock
50000
D
Warrant (Right to Buy)
2.47
Common Stock
50000
D
Stock Option (Right to Buy)
2.5
2015-02-18
2019-02-18
Common Stock
12500
D
Stock Option (Right to Buy)
3
2016-02-18
2020-02-18
Common Stock
12500
D
A total of 25,000 Common Stock Warrants are to vest, if earned, upon the Company signing a second clinical trial agreement in the United States. The Common Stock Warrants shall expire three years from the vesting date.
A total of 25,000 Common Stock Warrants are to vest, if earned, upon the Company signing an agreement with a laboratory/group certified through the CLIA for the use of the Company's proprietary screening kits and devices for the detection of certain diseases in humans in the United States. The Common Stock Warrants shall expire three years from the vesting date.
A total of 50,000 Common Stock Warrants are to vest, if earned, on the date the Company receives approval from the FDA for the sale and distribution in the United States of its first proprietary screening kit or device for the detection of a certain disease. The Common Stock Warrants shall expire three years from the vesting date.
A total of 50,000 Common Stock Warrants are to vest, if earned, on the date the Company receives approval from the FDA for the sale and distribution in the United States of its second proprietary screening kit or device for the detection of a certain disease. The Common Stock Warrants shall expire three years from the vesting date.
A total of 25,000 Stock Options were granted on August 18, 2014 under the Company's 2011 Equity Incentive Plan. The Options vest in two equal installments at 6 months and at 18 months from the date of grant, and expire four years from the vesting date.
The reporting person has served in a part-time capacity as the Chief Medical Officer and Head of U.S. Operations of VolitionRx Limited since March 2013, and also concurrently held positions between January 2013 and October 2015 with other publicly-held companies. The reporting person transitioned to full-time, employment status as the Chief Medical Officer and Head of U.S. Operations, and entered into an Employment Agreement, with VolitionRx Limited, effective January 1, 2016 (the indicated "Date of Event Requiring Statement").
/s/ Jason Terrell, M.D.
2016-01-01